Funder: National Institutes of Health
Due Dates: March 13, 2025 | December 4, 2025 | February 19, 2026
Funding Amounts: Up to $225,000 in direct costs for a 1-year project; NIH anticipates 2–3 awards per cycle.
Summary: Supports planning and strategy development for next-generation HIV treatments and prevention, enabling IND submission to FDA.
Key Information: Clinical trials are not allowed; funding supports preclinical planning and IND-enabling activities only.